Loading...
*  Factor X
Heparin (unfractionated heparin) and its derivatives low molecular weight heparin (LMWH) bind to a plasma cofactor, ... The affinity of unfractionated heparin and the various LMWHs for Factor Xa varies considerably. The efficacy of heparin-based ... This inactivation of Factor Xa by heparins is termed "indirect" since it relies on the presence of AT and not a direct ... LMWH shows increased inactivation of Factor Xa compared to unfractionated heparin, and fondaparinux, an agent based on the ...
*  Heparin cofactor II
2002). "Contribution of basic residues of the A helix of heparin cofactor II to heparin- or dermatan sulfate-mediated thrombin ... Mutations in this gene are associated with heparin cofactor II deficiency. Heparin Cofactor II deficiency can lead to increased ... 2004). "Studies on the effect of calcium in interactions between heparin and heparin cofactor II using surface plasmon ... heparin cofactor activities in a family with hereditary antithrombin III deficiency: evidence for a second heparin cofactor in ...
*  Bemiparin sodium
Enoxaparin has 4500 g/mol) These heparins have lower anti-thrombin activity than classical LMWHs and act mainly on factor Xa, ... Bemiparin is an antithrombotic and belongs to the group of low molecular weight heparins (LMWH). Like semuloparin, bemiparin is ... Plan├Ęs, A. (2003). "Review of bemiparin sodium - a new second-generation low molecular weight heparin and its applications in ... "A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and ...
*  Parnaparin sodium
Parnaparin is an antithrombotic and belongs to the group of low molecular weight heparins. parnaparin at the US National ... a low-molecular-weight heparin, prevents P-selectin-dependent formation of platelet-leukocyte aggregates in human whole blood ...
*  Discovery and development of direct thrombin inhibitors
HIT is a very serious adverse event related to heparin and occurs with both unfractionated heparin and LMWH, although to a ... In the 1980s low molecular-weight heparin (LMWH) were developed. They are derived from heparin by enzymatic or chemical ... and William Henry Howell discovered the anticoagulant heparin, which they isolated from the liver (hepar). Heparin remains one ... Hirsh, Jack; Raschke, Robert (2004). "Heparin and Low-Molecular-Weight Heparin The Seventh ACCP Conference on Antithrombotic ...
*  Discovery and development of direct Xa inhibitors
Chains of natural heparin can vary from 5.000 to 40.000 Daltons. In the 1980s Low molecular weight heparin (LMWH) were ... Heparin was discovered by Jay McLean and William Henry Howell in 1916, it was first isolated from a canine liver, which in ... Heparin targets multiple factors in the blood coagulation cascade, one of them being FXa. At first, it had many side effects ... Unlike older drugs, e.g. heparin, DX-9065a is selective for FXa compared to thrombin even though FXa and thrombin are similar ...
*  Dalteparin sodium
Dalteparin is a low molecular weight heparin. It is marketed as Fragmin by Pfizer Inc. Like other low molecular weight heparins ... Dalteparin is not superior to unfractionated heparin in preventing blood clots. Heparins are cleared by the kidneys, but ... "Low-molecular-weight heparin versus a Coumadin for the prevention of recurrent venous thromboembolism in patients with cancer ... "Dalteparin versus unfractionated heparin in critically ill patients". doi:10.1056/NEJMoa1014475. Douketis J, Cook D, Meade M, ...
*  Thrombin
Heparin increases the affinity of antithrombin to thrombin (as well as factor Xa). The direct thrombin inhibitors, a newer ...
*  Protamine
... sulfate is an antidote for heparin overdose. A chain shortened version of protamine also acts as a potent heparin ... Carr JA, Silverman N (Oct 1999). "The heparin-protamine interaction. A review". The Journal of Cardiovascular Surgery. 40 (5): ... a potent but nontoxic antagonist to heparin/low molecular weight protamine". ASAIO Journal. 46 (4): 435-9. doi:10.1097/00002480 ... and interventional radiology procedures to neutralize the anti-clotting effects of heparin. Adverse effects include increased ...
*  Platelet factor 4
The heparin:PF4 complex is the antigen in heparin-induced thrombocytopenia, an idiosyncratic autoimmune reaction to the ... Horne MK (1993). "The effect of secreted heparin-binding proteins on heparin binding to platelets". Thromb. Res. 70 (1): 91-98 ... Its major physiologic role appears to be neutralization of heparin-like molecules on the endothelial surface of blood vessels, ... Warkentin TE, Makris M, Jay RM, Kelton JG (July 2008). "A spontaneous prothrombotic disorder resembling heparin-induced ...
*  Fondaparinux
One potential advantage of fondaparinux over LMWH or unfractionated heparin is that the risk for heparin-induced ... Within heparin and heparin sulfate this monomeric sequence is thought to form the high-affinity binding site for the anti- ... In contrast to heparin, fondaparinux does not inhibit thrombin. Fondaparinux is given subcutaneously daily. Clinically, it is ... Unlike direct factor Xa inhibitors, it mediates its effects indirectly through antithrombin III, but unlike heparin, it is ...
*  Glycosaminoglycan
CSGAGs Endogenous heparin is localized and stored in secretory granules of mast cells. Histamine that is present within the ... In the clinic, heparin is administered as an anticoagulant and is also the first line choice for thromboembolic diseases. ... Heparin/heparan sulfate (HSGAGs) and chondroitin sulfate/dermatan sulfate (CSGAGs) are synthesized in the Golgi apparatus, ... CSGAGs interact with heparin binding proteins, specifically dermatan sulfate interactions with fibroblast growth factor FGF-2 ...
*  Tinzaparin sodium
Tinzaparin is an antithrombotic drug in the heparin group. It is a low molecular weight heparin (LMWH) marketed as Innohep ...
*  Heparin
A fractionated version of heparin, known as low molecular weight heparin is also available. Heparin is a naturally occurring ... Because danaparoid does not contain heparin or heparin fragments, cross-reactivity of danaparoid with heparin-induced ... heparin is a polymer of varying chain size. Unfractionated heparin (UFH) as a pharmaceutical is heparin that has not been ... It may be used in those who overdose on heparin or to reverse heparin's effect when it is no longer needed. Heparin's normal ...
*  Heparin lyase
The systematic name of this enzyme class is heparin lyase. Other names in common use include heparin eliminase, and heparinase ... In enzymology, a heparin lyase (EC 4.2.2.7) is an enzyme that catalyzes the chemical reaction Eliminative cleavage of ... Hovingh P, Linker A (1970). "The enzymatic degradation of heparin and heparitin sulfate. 3 Purification of a heparitinase and a ...
*  Heparin necrosis
... is a cutaneous condition and usually occurs between days 5 and 10 of heparin therapy. Warfarin necrosis List ...
*  Heparin-induced thrombocytopenia
While heparin was discovered in the 1930s, HIT was not reported until the 1960s. Heparin may be used for both prevention and ... Heparin occurs naturally in the human body, but the development of HIT antibodies suggests heparin may act as a hapten, and ... While heparin was introduced for clinical use in the late 1930s, new thrombosis in people treated with heparin was not ... Formation of PF4-heparin antibodies is common in people receiving heparin, but only a proportion of these develop ...
*  Heparin mimicking polymers
... are synthetic compounds that possess similar characteristics to heparin, that is it can be used ... Heparin is widely used as a clinical anticoagulant however, it possesses drawbacks creating a need for synthetic heparin ... Heparin-mimicking polymers can be designed to exhibit shape memory behavior. Heparin mimicking polymers can be characterized by ... Additionally prolonged use of heparin results in heparin induced thrombocytopenia. Three aspects of synthetic mimicking ...
*  2008 Chinese heparin adulteration
... due to contamination of the raw heparin stock imported from China. The raw material for the recalled heparin batches was ... The raw heparin batches were found to have been cut from 2-60% with the counterfeit substance, and motivation for the ... "Heparin's Deadly Side Effects". Time magazine. 2008. Archived from the original on 21 November 2008. Retrieved 2008-11-16. A ... In March 2008, major recalls of heparin, a substance widely used as an injectable anticoagulant, were announced by the U.S. ...
*  Low molecular weight heparin
Differences from heparin (i.e. "unfractionated heparin") include: Average molecular weight: heparin is about 15 kDa and LMWH is ... Smaller risk of heparin-induced thrombocytopenia, a potential side effect of heparin. The anticoagulant effects of heparin are ... Heparin and low-molecular-weight-heparin. Thromb Haemost 2008; 99: 807-818. Xu, Y.; Masuko, S.; Takieddin, M.; Xu, H.; Liu, R ... Various methods of heparin depolymerisation are used in the manufacture of low-molecular-weight heparin. These are listed below ...
*  Heparin-binding EGF-like growth factor
1994). "Characterization of sequences within heparin-binding EGF-like growth factor that mediate interaction with heparin". J. ... Heparin-binding EGF-like growth factor (HB-EGF) is a member of the EGF family of proteins that in humans is encoded by the ... Heparin-binding EGF-like growth factor has been shown to interact with NRD1, Zinc finger and BTB domain-containing protein 16 ... 1991). "A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF". Science. 251 (4996): 936-9. ...
*  DMOZ - Health: Pharmacy: Drugs and Medications: H: Heparin
All sites related to the drug Heparin - an Antithrombotic. ... Heparin Manufacturer of heparin and heparin-like ...
*  Roger W. Robinson
Engelberg, Hyman (1978). Heparin. New York: Basel. ISBN 3805528922. Likar, Ivan (1985). Atherosclerosis : cattle as a model for ... Robinson recognized the role of cholesterol and diet in atherosclerotic heart disease and demonstrated that heparin prevents ...
*  Thrombocytopenia
Discontinuation of heparin is critical in a case of heparin-induced thrombocytopenia (HIT). Beyond that, however, clinicians ... Ahmed, I; Majeed, A; Powell, R (2007). "Heparin induced thrombocytopenia: diagnosis and management update". Postgraduate ... Warkentin, Theodore E.; Greinacher, Andreas (2007-07-23). Heparin-Induced Thrombocytopenia. CRC Press. ISBN 9781439826423. ...
*  heparan sulfate)-glucosamine 3-sulfotransferase 1
Other names in common use include heparin-glucosamine 3-O-sulfotransferase, 3'-phosphoadenylyl-sulfate:heparin-glucosamine 3-O- ... Kusche M, Backstrom G, Riesenfeld J, Petitou M, Choay J, Lindahl U (1988). "Biosynthesis of heparin. O-sulfation of the ...